Special Issue

African Swine Fever Virus Immunotherapies and Vaccine Development

Message from the Guest Editors

ASFV affects both domestic pigs and wild boars, resulting in a significant economic impact on the global swine industry. Currently, there are no safe and effective vaccines or treatments for ASFV. Recent outbreaks have renewed the urgency to develop effective immunotherapies and vaccines to prevent and control ASFV. This Special Issue discusses recent advancements, innovative strategies, and ongoing research in ASFV immunology, vaccine development, and therapeutic interventions. Specifically, it will explore the immunological mechanisms involved in ASFV infection, candidate vaccines, therapeutic strategies, and diagnostic tools. We encourage submissions that address both the fundamental and applied aspects of ASFV immunology, offering new insights into potential solutions for combating this disease. We welcome original research articles and reviews in this Special Issue. Typical research areas may include:

- Immunology and vaccine development
- ASFV pathogenesis and immune evasion
- Vaccine candidates and development of vaccine strategies
- Diagnostics and technologies for ASFV
- Challenges and future directions in ASFV vaccine development

Guest Editors

Prof. Dr. Tao Feng

1. State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
2. Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou 730046, China

Dr. Xiaodong Qin

State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China

Deadline for manuscript submissions

30 November 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/231086

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI